‘We’ll Be First With Off-The-Shelf CAR-T,’ Vows Precision Biosciences – And Hopes To Win Over Gene-Editing Skeptics
Aiming To Help Patients Who Fail Auto CAR-Ts
As it and its competitors have failed on the first test of durability with their allogeneic CAR-T candidates, Precision Biosciences is looking to cross the line in a sub-group of responders – as well as prove the value of its gene-editing platform.
You may also be interested in...
Precision’s Allo CAR-T Inches Closer To Filling Post-Auto CAR-T Niche
The company provided Phase I/IIa data for allogeneic CAR-T PBCAR0191 showing a high response rate and signs of durability in aggressive NHL patients relapsing after autologous CAR-T.
SpringWorks Targets Rare Tumors, But Myeloma Is The Mother Lode
The company aims to file for desmoid tumors in the second half of 2022, but it has more than half a dozen combination programs with BCMA-targeting therapies in multiple myeloma.
Precision Picks New CEO To Tackle Gene Editing’s Commercial Challenges
Precision is looking ahead to market access challenges for its off-the-shelf CAR-T and in vivo gene-editing therapies.